Overview
Retatrutide is a triple receptor agonist, engaging GLP-1, GIP, and glucagon receptor pathways simultaneously — the broadest receptor coverage of any compound in this class currently in research use.
The Rexora Rexora Retatrutide 50mg pen supplies this compound pre-filled at a fixed concentration, removing the reconstitution step required with a lyophilised vial. Nova Biolabs supplies it from UK domestic stock.
Key Research Areas
Triple Receptor Pathway Research
Combined GLP-1, GIP, and glucagon receptor engagement makes Retatrutide a key tool for studying multi-pathway metabolic signalling in a single model.
Comparative Agonist Studies
Its broader receptor profile relative to dual and single-agonist compounds supports comparative research into incremental pathway contributions.
Energy Expenditure Research
The added glucagon receptor component distinguishes Retatrutide from GLP-1/GIP-only compounds in models examining energy expenditure alongside appetite signalling.
Pre-Filled Pen Delivery Research
The Rexora pen format supplies a fixed, pre-measured dose without a separate reconstitution step, useful where dosing consistency across research sessions matters.
Product Specifications
| Format | Pre-filled pen, ready to use |
| Content | 50mg Retatrutide |
| Grade | Research Grade |
| Storage | Refrigerate at 2–8°C. Do not freeze. |
| Origin | UK domestic stock |
| Research use | In vitro / laboratory use only |